Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms...

Benzinga · Oct 17 19:39

Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms Of Progression-free And Overall Survival

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms...

Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms Of Progression-free And Overall Survival

Risk Disclaimer